GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » TSH Biopharm Corp Ltd (ROCO:8432) » Definitions » Debt-to-Equity

TSH Biopharm (ROCO:8432) Debt-to-Equity : 0.01 (As of Mar. 2024)


View and export this data going back to 2012. Start your Free Trial

What is TSH Biopharm Debt-to-Equity?

TSH Biopharm's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was NT$6.5 Mil. TSH Biopharm's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was NT$0.0 Mil. TSH Biopharm's Total Stockholders Equity for the quarter that ended in Mar. 2024 was NT$1,276.6 Mil. TSH Biopharm's debt to equity for the quarter that ended in Mar. 2024 was 0.01.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for TSH Biopharm's Debt-to-Equity or its related term are showing as below:

ROCO:8432' s Debt-to-Equity Range Over the Past 10 Years
Min: 0   Med: 0   Max: 0.06
Current: 0.01

During the past 13 years, the highest Debt-to-Equity Ratio of TSH Biopharm was 0.06. The lowest was 0.00. And the median was 0.00.

ROCO:8432's Debt-to-Equity is ranked better than
99.88% of 845 companies
in the Drug Manufacturers industry
Industry Median: 0.3 vs ROCO:8432: 0.01

TSH Biopharm Debt-to-Equity Historical Data

The historical data trend for TSH Biopharm's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

TSH Biopharm Debt-to-Equity Chart

TSH Biopharm Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Debt-to-Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only - 0.01 0.01 0.06 0.01

TSH Biopharm Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Debt-to-Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.01 0.01 0.01 0.01 0.01

Competitive Comparison of TSH Biopharm's Debt-to-Equity

For the Drug Manufacturers - Specialty & Generic subindustry, TSH Biopharm's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


TSH Biopharm's Debt-to-Equity Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, TSH Biopharm's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where TSH Biopharm's Debt-to-Equity falls into.



TSH Biopharm Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

TSH Biopharm's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as

TSH Biopharm's Debt to Equity Ratio for the quarter that ended in Mar. 2024 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


TSH Biopharm  (ROCO:8432) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.


Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.


TSH Biopharm Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of TSH Biopharm's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.


TSH Biopharm (ROCO:8432) Business Description

Traded in Other Exchanges
N/A
Address
No.3-1, Park Street, 3rd Floor-1, Nangang District, Taipei, TWN, 115
TSH Biopharm Corp Ltd is engaged in the sale of a variety of pharmaceuticals, chemical drugs and biotechnology services. The Company's revenue is earned domestically.

TSH Biopharm (ROCO:8432) Headlines

No Headlines